VCEL – Vericel Corporation
Vericel CorporationVCEL
$59.03Name : Vericel Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,012,287,232.00
EPSttm : 0.64
Vericel Corporation
$59.03
1.10%$0.64
VCEL — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
10.39
Margin Of Safety %
-40
Put/Call OI Ratio
0.65
EPS Next Q Diff
-0.33
EPS Last/This Y
0.19
EPS This/Next Y
0.33
Price
59.05
Target Price
63.57
Analyst Recom
1.25
Performance Q
31.97
Upside
-62.6%
Beta
1.01
Ticker: VCEL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | VCEL | 40.6 | 1.20 | 999.99 | 547 |
| 2026-10-13 | VCEL | 40.33 | 1.21 | 0.00 | 550 |
| 2026-10-14 | VCEL | 40.17 | 1.18 | 0.00 | 557 |
| 2026-10-15 | VCEL | 40.93 | 1.13 | 0.00 | 567 |
| 2026-10-16 | VCEL | 40.14 | 1.11 | 1.54 | 571 |
| 2026-10-19 | VCEL | 40.35 | 0.97 | 0.00 | 387 |
| 2026-10-20 | VCEL | 40.54 | 0.97 | 0.00 | 387 |
| 2026-10-21 | VCEL | 40.94 | 0.96 | 0.00 | 390 |
| 2026-10-22 | VCEL | 42.98 | 0.94 | 0.00 | 395 |
| 2026-10-23 | VCEL | 42.52 | 0.92 | 0.00 | 398 |
| 2026-10-26 | VCEL | 43.02 | 0.91 | 0.25 | 400 |
| 2026-10-27 | VCEL | 43.3 | 0.92 | 0.00 | 401 |
| 2026-10-28 | VCEL | 41.03 | 0.91 | 0.00 | 403 |
| 2026-10-29 | VCEL | 42.89 | 0.86 | 0.14 | 415 |
| 2026-10-30 | VCEL | 40.22 | 0.84 | 0.00 | 422 |
| 2026-11-02 | VCEL | 40.54 | 0.81 | 0.00 | 431 |
| 2026-11-03 | VCEL | 41.09 | 0.79 | 0.25 | 438 |
| 2026-11-04 | VCEL | 45.44 | 0.77 | 0.25 | 448 |
| 2026-11-05 | VCEL | 51.67 | 0.75 | 0.01 | 458 |
| 2026-11-06 | VCEL | 54.38 | 0.66 | 0.00 | 498 |
| 2026-11-09 | VCEL | 58.39 | 0.65 | 0.43 | 506 |
| 2026-11-10 | VCEL | 59.05 | 0.65 | 0.02 | 519 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | VCEL | 40.62 | -44.0 | - | 0.52 |
| 2026-10-13 | VCEL | 40.30 | -44.0 | - | 0.52 |
| 2026-10-14 | VCEL | 40.21 | -44.0 | - | 0.52 |
| 2026-10-15 | VCEL | 40.99 | -44.0 | - | 0.52 |
| 2026-10-16 | VCEL | 40.10 | -44.0 | - | 0.52 |
| 2026-10-19 | VCEL | 40.37 | -44.0 | - | 0.52 |
| 2026-10-20 | VCEL | 40.37 | -44.0 | - | 0.52 |
| 2026-10-21 | VCEL | 40.58 | -44.0 | - | 0.52 |
| 2026-10-22 | VCEL | 42.99 | -44.0 | - | 0.52 |
| 2026-10-23 | VCEL | 42.51 | -44.0 | - | 0.52 |
| 2026-10-26 | VCEL | 43.03 | -44.0 | - | 0.52 |
| 2026-10-27 | VCEL | 43.30 | -44.0 | - | 0.52 |
| 2026-10-28 | VCEL | 41.08 | -44.0 | - | 0.52 |
| 2026-10-29 | VCEL | 42.93 | -44.0 | - | 0.52 |
| 2026-10-30 | VCEL | 40.24 | -44.0 | - | 0.52 |
| 2026-11-02 | VCEL | 40.50 | -44.0 | - | 0.52 |
| 2026-11-03 | VCEL | 41.11 | -44.0 | - | 0.52 |
| 2026-11-04 | VCEL | 45.46 | -44.0 | - | 0.52 |
| 2026-11-05 | VCEL | 51.81 | -44.0 | - | 0.52 |
| 2026-11-06 | VCEL | 54.58 | 18.7 | - | 0.52 |
| 2026-11-09 | VCEL | 58.44 | 18.7 | - | 0.52 |
| 2026-11-10 | VCEL | 59.05 | 18.7 | - | 0.52 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | VCEL | -15.35 | -2.25 | 10.28 |
| 2026-10-13 | VCEL | -15.35 | -2.25 | 10.28 |
| 2026-10-14 | VCEL | -15.35 | -2.25 | 10.28 |
| 2026-10-15 | VCEL | -15.35 | -2.25 | 10.28 |
| 2026-10-16 | VCEL | -15.35 | -2.25 | 10.28 |
| 2026-10-19 | VCEL | -15.34 | -2.18 | 10.28 |
| 2026-10-20 | VCEL | -15.34 | -2.18 | 10.28 |
| 2026-10-21 | VCEL | -15.35 | -2.18 | 10.28 |
| 2026-10-22 | VCEL | -15.35 | -2.18 | 10.28 |
| 2026-10-23 | VCEL | -15.35 | -2.18 | 10.28 |
| 2026-10-26 | VCEL | -15.34 | -2.29 | 10.28 |
| 2026-10-27 | VCEL | -15.35 | -2.29 | 10.35 |
| 2026-10-28 | VCEL | -15.35 | -2.29 | 10.35 |
| 2026-10-29 | VCEL | -15.35 | -2.29 | 10.35 |
| 2026-10-30 | VCEL | -15.35 | -2.29 | 10.35 |
| 2026-11-02 | VCEL | -15.35 | -2.37 | 10.35 |
| 2026-11-03 | VCEL | -15.35 | -2.37 | 10.35 |
| 2026-11-05 | VCEL | -15.35 | -2.37 | 10.35 |
| 2026-11-06 | VCEL | -15.35 | -2.37 | 10.35 |
| 2026-11-09 | VCEL | -16.80 | -1.39 | 10.39 |
| 2026-11-10 | VCEL | -22.13 | -1.39 | 10.39 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.27
Avg. EPS Est. Current Quarter
0.53
Avg. EPS Est. Next Quarter
-0.06
Insider Transactions
-22.13
Institutional Transactions
-1.39
Beta
1.01
Average Sales Estimate Current Quarter
112
Average Sales Estimate Next Quarter
79
Fair Value
35.33
Quality Score
89
Growth Score
92
Sentiment Score
99
Actual DrawDown %
6.3
Max Drawdown 5-Year %
-60.2
Target Price
63.57
P/E
93.43
Forward P/E
62.48
PEG
0.99
P/S
9.29
P/B
7.84
P/Free Cash Flow
52.03
EPS
0.63
Average EPS Est. Cur. Y
0.52
EPS Next Y. (Est.)
0.85
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
10.27
Relative Volume
2.17
Return on Equity vs Sector %
-17.6
Return on Equity vs Industry %
2.1
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
VCEL
Healthcare
$59.03
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
82.3
Range 1M
95.8%
Sup Dist
4.8%
Momentum Growth
Ride accelerating trends
WATCH
EPS Yr
137%
EPS NY
24.6%
52W%
97.2%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-35.3% upside
Upside
-35.3%
Quality
89
MoS
-40%
VCEL — P/E HistoricalBiotechnology
Vericel CorporationSector: Healthcare
Industry: Biotechnology
Employees: 398
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
VCEL
Latest News
—
Caricamento notizie per VCEL…
stock quote shares VCEL – Vericel Corporation Stock Price stock today
news today VCEL – Vericel Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch VCEL – Vericel Corporation yahoo finance google finance
stock history VCEL – Vericel Corporation invest stock market
stock prices VCEL premarket after hours
ticker VCEL fair value insiders trading